July 9, 2020 / 12:17 PM / a month ago

BRIEF-Bayer's Finerenone Meets Primary Endpoint In Phase Iii Fidelio-Dkd Renal Outcomes Study

July 9 (Reuters) - Bayer AG:

* BAYER’S FINERENONE MEETS PRIMARY ENDPOINT IN PHASE III FIDELIO-DKD RENAL OUTCOMES STUDY IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND TYPE 2 DIABETES

* BAYER - FINERENONE REDUCED COMBINED PRIMARY ENDPOINT OF RISK OF CHRONIC KIDNEY DISEASE PROGRESSION, KIDNEY FAILURE/KIDNEY DEATH VERSUS PLACEBO WHEN ADDED TO STANDARD OF CARE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below